The estimated Net Worth of Thomas R Ii Staab is at least $1.86 Milione dollars as of 16 May 2019. Thomas Staab owns over 9,750 units of Biocryst Pharmaceuticals stock worth over $967,610 and over the last 13 years Thomas sold BCRX stock worth over $896,331.
Thomas has made over 45 trades of the Biocryst Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Thomas sold 9,750 units of BCRX stock worth $74,588 on 16 May 2019.
The largest trade Thomas's ever made was exercising 36,455 units of Biocryst Pharmaceuticals stock on 16 March 2017 worth over $108,271. On average, Thomas trades about 5,224 units every 24 days since 2011. As of 16 May 2019 Thomas still owns at least 125,176 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Thomas Staab stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... e Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: